Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) saw some unusual options trading activity on Wednesday. Investors purchased 4,063 put options on the stock. This is an increase of approximately 2,362% compared to the typical volume of 165 put options.
In other news, CFO Sherry Aulin sold 18,709 shares of the company's stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total value of $770,997.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gary Patou sold 4,891 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $41.08, for a total value of $200,922.28. Following the transaction, the director now directly owns 23,573 shares in the company, valued at approximately $968,378.84. The trade was a 17.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.52% of the company's stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC increased its position in Xenon Pharmaceuticals by 2.2% during the third quarter. FMR LLC now owns 6,917,684 shares of the biopharmaceutical company's stock worth $272,349,000 after buying an additional 149,511 shares during the last quarter. Driehaus Capital Management LLC boosted its stake in shares of Xenon Pharmaceuticals by 2.3% during the 2nd quarter. Driehaus Capital Management LLC now owns 4,419,472 shares of the biopharmaceutical company's stock worth $172,315,000 after acquiring an additional 97,732 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Xenon Pharmaceuticals by 0.4% during the 3rd quarter. Wellington Management Group LLP now owns 3,843,447 shares of the biopharmaceutical company's stock valued at $151,317,000 after acquiring an additional 15,226 shares during the last quarter. Braidwell LP raised its stake in shares of Xenon Pharmaceuticals by 5.7% in the 3rd quarter. Braidwell LP now owns 2,707,255 shares of the biopharmaceutical company's stock valued at $106,585,000 after acquiring an additional 146,682 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in Xenon Pharmaceuticals by 144.2% in the 3rd quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company's stock worth $100,506,000 after purchasing an additional 1,507,135 shares during the last quarter. Institutional investors own 95.45% of the company's stock.
XENE opened at $38.42 on Thursday. The company has a market capitalization of $2.93 billion, a PE ratio of -13.62 and a beta of 1.19. Xenon Pharmaceuticals has a fifty-two week low of $35.53 and a fifty-two week high of $50.99. The business has a 50-day moving average of $41.73 and a 200-day moving average of $40.50.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same quarter in the prior year, the business posted ($0.73) EPS. On average, equities research analysts expect that Xenon Pharmaceuticals will post -3.1 earnings per share for the current fiscal year.
Several analysts recently commented on XENE shares. William Blair raised shares of Xenon Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. Royal Bank of Canada reiterated an "outperform" rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, September 3rd. Raymond James restated an "outperform" rating and set a $50.00 price target on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. HC Wainwright reiterated a "buy" rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, December 12th. Finally, Needham & Company LLC restated a "buy" rating and issued a $60.00 target price on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $56.00.
View Our Latest Research Report on XENE
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.